共 25 条
[11]
Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., Apffelstaedt J., Smith R., Sleeboom H.P., Janicke F., Pluzanska A., Dank M., Becquart D., Bapsy P.P., Salminen E., Snyder R., Lassus M., Verbeek J.A., Staffler B., Chaudri-Ross H.A., Dugan M., Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the international letrozole breast cancer group, Journal of Clinical Onc
[12]
Paridaens R., Dirix L., Beex L., Et al., Exemestane is active and well tolerated as first-line hormonal therapy of metastatic breast cancer patients: Results of a randomised phase II trial, Proc Am Soc Clin Oncol, 19, (2000)
[13]
Jones S.E., Vogel C., Arkhipov A., Fehrenbacher L., Eisenberg P., Cooper B., Honig S., Polli A., Whaley F., Di Salle E., Tiffany J., Consonni A., Miller L., Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer, Journal of Clinical Oncology, 17, 11, pp. 3418-3425, (1999)
[14]
Lonning P., Bajetta E., Murray R., Tubiana M., Eisenberg P., Mickiewicz E., Fowst C., Arkhipov A., Polli A., Di Salle E., Massimini G., A phase 1I study of exemestane in metastatic breast cancer patients failing non-steriodal aromatase inhibitors, Breast Cancer Res Treat, 50, (1998)
[15]
Howell A., Robertson J., Quaresma A., Aschermannova A., Mauriac L., Kleeberg U., Vergote I., Erikstein B., Webster A., Morris C., Comparison of efficacy and tolerability of Faslodex (ICI 182,780) with Arimidex (anastrozole) in postmenopausal (PM) women with advanced breast cancer (ABC) - Preliminary results, Breast Cancer Res Treat, 64, (2000)
[16]
Osborne C., Pippen J., Jones S., Parker L., Ellis M., Come S., Gertler S., May J., Burton G., Webster A., Morris C., Dimery I., Elledge R., Faslodex (ICI 182,780) shows longer duration of response compared to Arimidex (anastrozole) in postmenopausal (PM) women with advanced breast caner (ABC), Breast Cancer Res Treat, 64, (2000)
[17]
Klijn J., Blarney R., Boccardo F., Et al., A new standard treatment for advanced breast cancer: A meta analysis of the combined hormonal agents trialists group (CHAF), EurJ Cancer, 34, (1998)
[18]
Cheung K., Forward D., Jackson L., Robertson J., The combined use of goserelin (Zoladex) and anastrozole (Arimidex) as second line endocrine therapy in premenopausal women with advanced breast cancer - A study of its clinical and endocrine effects, Eur J Cancer, 37, (2001)
[19]
Tamoxifen for early breast cancer: An overview of the randomised trials, Lancet, 351, pp. 1451-1467, (1998)
[20]
Fisher M.D., O'Shaughnessy J., Sparano J.A., Anastrozole may be superior to Tamoxifen as adjuvant treatment for postmenopausal patients with breast cancer, Clinical Breast Cancer, 2, 4, pp. 269-271, (2002)